share_log

Abbott Laboratories | 10-Q: Q3 2024 Earnings Report

Abbott Laboratories | 10-Q: Q3 2024 Earnings Report

雅培 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/01 05:16

Moomoo AI 已提取核心信息

Abbott Laboratories reported Q3 2024 net sales of $10.635 billion, up 4.9% year-over-year. Excluding foreign exchange impact, sales grew 7.4%. Medical Devices segment led growth with an 11.7% increase, while COVID-19 testing sales declined. Gross profit margin improved to 51.4% from 49.7% in Q3 2023.R&D expenses rose 6.1% to $713 million, while selling, general and administrative expenses increased 6.3%. Abbott approved restructuring plans to streamline operations, recording $60 million in employee-related charges. The company maintained its AA- and Aa3 credit ratings from S&P and Moody's respectively.Abbott repurchased approximately 7 million common shares for $750 million in Q3. The board authorized a new $7 billion share repurchase program in October 2024. Abbott declared a quarterly dividend of $0.55 per share, up 7.8% from 2023. The company faces ongoing tax disputes with the IRS and continues to analyze potential impacts of proposed international tax system changes.
Abbott Laboratories reported Q3 2024 net sales of $10.635 billion, up 4.9% year-over-year. Excluding foreign exchange impact, sales grew 7.4%. Medical Devices segment led growth with an 11.7% increase, while COVID-19 testing sales declined. Gross profit margin improved to 51.4% from 49.7% in Q3 2023.R&D expenses rose 6.1% to $713 million, while selling, general and administrative expenses increased 6.3%. Abbott approved restructuring plans to streamline operations, recording $60 million in employee-related charges. The company maintained its AA- and Aa3 credit ratings from S&P and Moody's respectively.Abbott repurchased approximately 7 million common shares for $750 million in Q3. The board authorized a new $7 billion share repurchase program in October 2024. Abbott declared a quarterly dividend of $0.55 per share, up 7.8% from 2023. The company faces ongoing tax disputes with the IRS and continues to analyze potential impacts of proposed international tax system changes.
雅培报告了2024年第三季度净销售额为1063.5亿美元，同比上涨4.9%。排除汇率影响后，销售增长了7.4%。医疗设备部门带动了增长，增长率为11.7%，而COVID-19检测销售下降。毛利润率从2023年第三季度的49.7%提高到51.4%。研发费用上升6.1%，达71300万美元，而销售、管理和一般费用增加了6.3%。雅培批准了重组计划以简化运营，记录了6000万美元的员工相关费用。公司保持了来自标准普尔和穆迪的AA-和Aa3信用评级。雅培在第三季度回购了大约700万普通股，耗资75000万美元。董事会于2024年10月授权了一项新的70亿美元股票回购计划。雅培宣布了每股0.55美元的季度股息，比2023年增长了7.8%。公司与美国国税局持续存在税务争议，并继续分析拟议国际税制变更的潜在影响。
雅培报告了2024年第三季度净销售额为1063.5亿美元，同比上涨4.9%。排除汇率影响后，销售增长了7.4%。医疗设备部门带动了增长，增长率为11.7%，而COVID-19检测销售下降。毛利润率从2023年第三季度的49.7%提高到51.4%。研发费用上升6.1%，达71300万美元，而销售、管理和一般费用增加了6.3%。雅培批准了重组计划以简化运营，记录了6000万美元的员工相关费用。公司保持了来自标准普尔和穆迪的AA-和Aa3信用评级。雅培在第三季度回购了大约700万普通股，耗资75000万美元。董事会于2024年10月授权了一项新的70亿美元股票回购计划。雅培宣布了每股0.55美元的季度股息，比2023年增长了7.8%。公司与美国国税局持续存在税务争议，并继续分析拟议国际税制变更的潜在影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间